Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ; Cancer and Leukemia Group B. Picus J, et al. Among authors: kaplan eb. Cancer. 2011 Feb 1;117(3):526-33. doi: 10.1002/cncr.25421. Epub 2010 Sep 22. Cancer. 2011. PMID: 20862750 Free PMC article. Clinical Trial.
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782.
Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ; Cancer and Leukemia Group B. Monk JP, et al. Cancer. 2012 Sep 1;118(17):4139-47. doi: 10.1002/cncr.26732. Epub 2011 Dec 16. Cancer. 2012. PMID: 22180287 Free PMC article. Clinical Trial.
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. Kelly WK, et al. J Clin Oncol. 2012 May 1;30(13):1534-40. doi: 10.1200/JCO.2011.39.4767. Epub 2012 Mar 26. J Clin Oncol. 2012. PMID: 22454414 Free PMC article. Clinical Trial.
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy.
Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. Halabi S, et al. Among authors: kaplan eb. J Natl Cancer Inst. 2013 Nov 20;105(22):1729-37. doi: 10.1093/jnci/djt280. Epub 2013 Oct 17. J Natl Cancer Inst. 2013. PMID: 24136890 Free PMC article. Clinical Trial.
118 results